Ewa Koscielniak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ewa Koscielniak has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Klingebiel
Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
5 shared publications - Ivo Leuschner
University of Kiel, Institute of Pediatric Pathology, Kiel, Germany
3 shared publications - Bernarda Kazanowska
Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wroclaw, Poland
2 shared publications - Gustaf Ljungman
Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden
2 shared publications Marc W. Muenter
Klinikum Stuttgart Olgahospital, Stuttgart, Germany
2 shared publications- Monika Scheer
Department of Pediatric Hematology and Oncology Charité—Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt‐Universität Zu Berlin Berlin Germany
2 shared publications
Latest Publications
- 4 January 2020
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 179 (5) , 749-756
Inequalities in diagnosis and registration of pediatric very rare tumors: a European study on pleuropulmonary blastoma
Very rare tumors (VRTs) account for up to 11% of childhood cancers. Dedicated national groups and registries only exist in some European countries. Pleuropulmonary blastoma (PPB) is a very rare intrathoracic pediatric tumor with a potentially severe prognosis. Due to its rarity, it sometimes goes unrecognized. We investigated PPB diagnostic capability and possible correlations between diagnostic performance and VRT-dedicated activities. The number of cases of PPB registered between 2000 and 2014 at pediatric oncology centers in Europe was compared with the number of expected cases. Data sources included VRT registries, population-based cancer registries, and hospital registries. Data were obtained for 25 countries, grouped into 4 geographical regions. The expected cases were 111, and the observed cases were 129. The observed-to-expected ratio was 1.86 for Northern Europe, 1.33 for Southern Europe, 1.22 for Central Europe, and 0.65 for Eastern Europe. More cases than expected were registered in all countries with an official VRT registry. Conclusion: The number of cases observed is consistent with expectations, but disparities exist across Europe. Difficulties in diagnosing PPB emerged in most Eastern countries. The incidence rate of PPB may be underestimated. The creation of VRT-dedicated groups and a European Registry for VRTs could help to reduce inequalities. What is Known: • Very rare pediatric tumors are often not recognized, despite representing almost 11% of childhood cancers . • Pleuropulmonary blastoma is a rare pediatric tumor with a poor prognosis. What is New: • The ability to diagnose and register pleuropulmonary blastoma varies in Europe.Registries dedicated to very rare pediatric tumors improve the diagnostic rates. • The incidence rate of pleuropulmonary blastoma may currently be underestimated
- 4 January 2020
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 179 (5) , 749-756
Inequalities in diagnosis and registration of pediatric very rare tumors: a European study on pleuropulmonary blastoma
Very rare tumors (VRTs) account for up to 11% of childhood cancers. Dedicated national groups and registries only exist in some European countries. Pleuropulmonary blastoma (PPB) is a very rare intrathoracic pediatric tumor with a potentially severe prognosis. Due to its rarity, it sometimes goes unrecognized. We investigated PPB diagnostic capability and possible correlations between diagnostic performance and VRT-dedicated activities. The number of cases of PPB registered between 2000 and 2014 at pediatric oncology centers in Europe was compared with the number of expected cases. Data sources included VRT registries, population-based cancer registries, and hospital registries. Data were obtained for 25 countries, grouped into 4 geographical regions. The expected cases were 111, and the observed cases were 129. The observed-to-expected ratio was 1.86 for Northern Europe, 1.33 for Southern Europe, 1.22 for Central Europe, and 0.65 for Eastern Europe. More cases than expected were registered in all countries with an official VRT registry. Conclusion: The number of cases observed is consistent with expectations, but disparities exist across Europe. Difficulties in diagnosing PPB emerged in most Eastern countries. The incidence rate of PPB may be underestimated. The creation of VRT-dedicated groups and a European Registry for VRTs could help to reduce inequalities. What is Known: • Very rare pediatric tumors are often not recognized, despite representing almost 11% of childhood cancers . • Pleuropulmonary blastoma is a rare pediatric tumor with a poor prognosis. What is New: • The ability to diagnose and register pleuropulmonary blastoma varies in Europe.Registries dedicated to very rare pediatric tumors improve the diagnostic rates. • The incidence rate of pleuropulmonary blastoma may currently be underestimated
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10527
Type, intensity, and duration of chemotherapy (CHT) and their correlation with prognosis of localized soft tissue Ewing tumors (STET): Experience of the Cooperative Weichteilsarkomstudiengruppe (CWS).
10527 Background: The optimal type and intensity of CHT in the treatment of STET is still a matter of debate. The CWS group has treated STET similar to rhabdomyosarcoma. We have analyzed the prognosis of STET in relation to the CHT regimens used in three consecutive CWS studies CWS-91, -96 and CWS- 2002P. Methods: 243 pts with localized STET were included. Their median age was 12 (range 0.1-29) yrs. In the CWS-91 pts with primary tumor resection (IRSG I and II) were treated with VACA (vincristine (VCR), actinomycin D (Act D), cyclophosphamide (CYC), doxorubicin (DOX), for 10 or 20 weeks. All other CWS-91 pts (high risk group, HRG) received EVAIA (ifosfamide (IFO) instead of CYC plus VP16) for 37 weeks. In the CWS-96 and CWS-2002P all STET pts were allocated to the HRG. In CWS-96 therapy was randomized: VAIA (IFO, DOX, Act D, VCR) vs. CEVAIE (Epi-DOX instead of DOX, plus carboplatin and VP16), for 25 weeks. In CWS-2002P VAIA (25 weeks) plus maintenance CHT with CYC and vinblastine (VBL) for 26 weeks were used. The cumulative doses varied: IFO 24-72 g/m², CYC 4.8-7.35 g/m², DOX 120-360 mg/m², Act D 3-9 mg/m², VP16 1.8-5.4 g/m². Irradiation was stratified depending on results of the primary or secondary resection and response. Results: 5 yr event free (EFS) and overall survival (OS) were 64% and 73%. The median observation time of survivors was 9 yrs. 5yr EFS and OS by study were: CWS-91 64 % and 72 %, CWS-96 57% and 70 %, CWS-2002P 78 % and 86 % respectively (n.s.). 5 yr EFS and OS for VACA arm were 79% and 90%. 5 yr EFS and OS by CHT for HRG were: EVAIA 57% and 65%, VAIA 64% and 80%, CEVAIE 45% and 54%, VAIA with CYC/VBL 84% and 87%, respectively (p = 0 .003). 5yr EFS and OS for irradiated (n = 181) vs. not irradiated (n = 48) patients were 63 % and 72% vs. 63% and 79%, respectively. Conclusions: The outcomes between CHT arms differed significantly: CEVAIA correlated with the worst outcome while VAIA with CYC/VBL showed the best results. A small group of low risk patients have an excellent prognosis with substantially reduced CHT. Ewing tumors are biologically heterogeneous and more diversification in therapy stratification is warranted to avoid overtreatment.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10527
Type, intensity, and duration of chemotherapy (CHT) and their correlation with prognosis of localized soft tissue Ewing tumors (STET): Experience of the Cooperative Weichteilsarkomstudiengruppe (CWS).
10527 Background: The optimal type and intensity of CHT in the treatment of STET is still a matter of debate. The CWS group has treated STET similar to rhabdomyosarcoma. We have analyzed the prognosis of STET in relation to the CHT regimens used in three consecutive CWS studies CWS-91, -96 and CWS- 2002P. Methods: 243 pts with localized STET were included. Their median age was 12 (range 0.1-29) yrs. In the CWS-91 pts with primary tumor resection (IRSG I and II) were treated with VACA (vincristine (VCR), actinomycin D (Act D), cyclophosphamide (CYC), doxorubicin (DOX), for 10 or 20 weeks. All other CWS-91 pts (high risk group, HRG) received EVAIA (ifosfamide (IFO) instead of CYC plus VP16) for 37 weeks. In the CWS-96 and CWS-2002P all STET pts were allocated to the HRG. In CWS-96 therapy was randomized: VAIA (IFO, DOX, Act D, VCR) vs. CEVAIE (Epi-DOX instead of DOX, plus carboplatin and VP16), for 25 weeks. In CWS-2002P VAIA (25 weeks) plus maintenance CHT with CYC and vinblastine (VBL) for 26 weeks were used. The cumulative doses varied: IFO 24-72 g/m², CYC 4.8-7.35 g/m², DOX 120-360 mg/m², Act D 3-9 mg/m², VP16 1.8-5.4 g/m². Irradiation was stratified depending on results of the primary or secondary resection and response. Results: 5 yr event free (EFS) and overall survival (OS) were 64% and 73%. The median observation time of survivors was 9 yrs. 5yr EFS and OS by study were: CWS-91 64 % and 72 %, CWS-96 57% and 70 %, CWS-2002P 78 % and 86 % respectively (n.s.). 5 yr EFS and OS for VACA arm were 79% and 90%. 5 yr EFS and OS by CHT for HRG were: EVAIA 57% and 65%, VAIA 64% and 80%, CEVAIE 45% and 54%, VAIA with CYC/VBL 84% and 87%, respectively (p = 0 .003). 5yr EFS and OS for irradiated (n = 181) vs. not irradiated (n = 48) patients were 63 % and 72% vs. 63% and 79%, respectively. Conclusions: The outcomes between CHT arms differed significantly: CEVAIA correlated with the worst outcome while VAIA with CYC/VBL showed the best results. A small group of low risk patients have an excellent prognosis with substantially reduced CHT. Ewing tumors are biologically heterogeneous and more diversification in therapy stratification is warranted to avoid overtreatment.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10529
Prognosis of patients with parameningeal rhabdomyosarcoma (PM-RMS): The long term results of five consecutive CWS studies 1981-2009.
10529 Background: PM sites (nasopharynx/nasal cavity, the middle ear, the paranasal sinuses, and the infratemporal fossa/pterygopalatine space) are considered as unfavorable factor in RMS. Due to their proximity to skull base they have high risk of meningeal impingement, including cranial nerve palsy (CNP), cranial base bony erosion (CBBE) and intracranial extension (ICE). Our goal was to compare treatment strategies and outcome of patients with localized PM RMS enrolled on five consecutive CWS studies -81 -86, -91, -96 and -2002P. Methods: A total of 404 patients were included. All patients received intensive chemotherapy (3 to 6 drugs: alkylating agents - cyclophosphamide or ifosfamide, actinomycin D, doxorubicin, vincristine, carboplatin and etoposide. Radiotherapy was indicated for all patients except for children < 1 year of age. Irradiation (RT) dose was stratified depending on meningeal involvement, response, histological subtype and age and varied between the studies (32 - 54,4 Gy). Accelarated hyperfractionation was recommended since CWS-86. Proton radiation was recommended if available. Results: The majority of tumors were classified into IRS Group III (95%) and had embryonal type (78%). 85% achieved complete remission, 22 % relapsed, 15% local. The 5yrs event free survival (EFS) and overall survival (OS) was 61% and 65%. 5yrs EFS by study was CWS-81: 42%, CWS-86: 63%, CWS-91: 63%, CWS-96: 62%, CWS 2002P: 66%. Patients with ICE had worst outcome but no difference was seen depending on CNP and CBBE. 92% of patients were irradiated. The median time from initiation of chemotherapy to RT was 14 weeks (range 2-30). 5yrs EFS depending on RT start ( < 10 weeks, > 10 < 20 weeks, > 20 < 30 weeks) did not differ (65%, 67%, 68%). Three patients groups depending on their RT dose: 32-36 Gy, 44-49 Gy, 50-55 Gy showed similar outcome (5yrs EFS 70% vs.68% vs. 67% respectively). Only patients irradiated with > 57 Gy or without RT had significantly worse outcome (5yrs EFS 30%). Conclusions: The outcome has improved between CWS-81 and CWS-86 only. No benefit of very early ( < 10 weeks) or higher irradiation doses was seen.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10529
Prognosis of patients with parameningeal rhabdomyosarcoma (PM-RMS): The long term results of five consecutive CWS studies 1981-2009.
10529 Background: PM sites (nasopharynx/nasal cavity, the middle ear, the paranasal sinuses, and the infratemporal fossa/pterygopalatine space) are considered as unfavorable factor in RMS. Due to their proximity to skull base they have high risk of meningeal impingement, including cranial nerve palsy (CNP), cranial base bony erosion (CBBE) and intracranial extension (ICE). Our goal was to compare treatment strategies and outcome of patients with localized PM RMS enrolled on five consecutive CWS studies -81 -86, -91, -96 and -2002P. Methods: A total of 404 patients were included. All patients received intensive chemotherapy (3 to 6 drugs: alkylating agents - cyclophosphamide or ifosfamide, actinomycin D, doxorubicin, vincristine, carboplatin and etoposide. Radiotherapy was indicated for all patients except for children < 1 year of age. Irradiation (RT) dose was stratified depending on meningeal involvement, response, histological subtype and age and varied between the studies (32 - 54,4 Gy). Accelarated hyperfractionation was recommended since CWS-86. Proton radiation was recommended if available. Results: The majority of tumors were classified into IRS Group III (95%) and had embryonal type (78%). 85% achieved complete remission, 22 % relapsed, 15% local. The 5yrs event free survival (EFS) and overall survival (OS) was 61% and 65%. 5yrs EFS by study was CWS-81: 42%, CWS-86: 63%, CWS-91: 63%, CWS-96: 62%, CWS 2002P: 66%. Patients with ICE had worst outcome but no difference was seen depending on CNP and CBBE. 92% of patients were irradiated. The median time from initiation of chemotherapy to RT was 14 weeks (range 2-30). 5yrs EFS depending on RT start ( < 10 weeks, > 10 < 20 weeks, > 20 < 30 weeks) did not differ (65%, 67%, 68%). Three patients groups depending on their RT dose: 32-36 Gy, 44-49 Gy, 50-55 Gy showed similar outcome (5yrs EFS 70% vs.68% vs. 67% respectively). Only patients irradiated with > 57 Gy or without RT had significantly worse outcome (5yrs EFS 30%). Conclusions: The outcome has improved between CWS-81 and CWS-86 only. No benefit of very early ( < 10 weeks) or higher irradiation doses was seen.
- Open Access
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 2, 32
Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models
Allogeneic stem cell transplantation (allo-SCT) has become an important treatment modality for patients with high-risk acute myeloid leukemia (AML) and is also under investigation for soft tissue sarcomas. The therapeutic success is still limited by minimal residual disease (MRD) status ultimately leading to patients’ relapse. Adoptive donor lymphocyte infusions based on MRD status using IL-15-expanded cytokine-induced killer (CIK) cells may prevent relapse without causing graft-versus-host-disease (GvHD). To generate preclinical data we developed mouse models to study anti-leukemic- and anti-tumor-potential of CIK cells in vivo. Immunodeficient mice (NOD/SCID/IL-2Rγc−, NSG) were injected intravenously with human leukemic cell lines THP-1, SH-2 and with human rhabdomyosarcoma (RMS) cell lines RH41 and RH30 at minimal doses required for leukemia or tumor engraftment. Mice transplanted with THP-1 or RH41 cells were randomly assigned for analysis of CIK cell treatment. Organs of mice were analyzed by flow cytometry as well as quantitative polymerase chain reaction for engraftment of malignant cells and CIK cells. Potential of CIK cells to induce GvHD was determined by histological analysis. Tissues of the highest degree of THP-1 cell expansion included bone marrow followed by liver, lung, spleen, peripheral blood (PB), and brain. RH30 and RH41 engraftment mainly took place in liver and lung, but was also detectable in spleen and PB. In spite of delayed CIK cell expansion compared with malignant cells, CIK cells injected at equal amounts were sufficient for significant reduction of RH41 cells, whereas against fast-expanding THP-1 cells 250 times more CIK than THP-1 cells were needed to achieve comparable results. Our preclinical in vivo mouse models showed a reliable 100% engraftment of malignant cells which is essential for analysis of anti-cancer therapy. Furthermore our data demonstrated that IL-15-activated CIK cells have potent cytotoxic capacity against AML and RMS cells without causing GvHD.
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 2, 32
Open AccessCytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models
Allogeneic stem cell transplantation (allo-SCT) has become an important treatment modality for patients with high-risk acute myeloid leukemia (AML) and is also under investigation for soft tissue sarcomas. The therapeutic success is still limited by minimal residual disease (MRD) status ultimately leading to patients’ relapse. Adoptive donor lymphocyte infusions based on MRD status using IL-15-expanded cytokine-induced killer (CIK) cells may prevent relapse without causing graft-versus-host-disease (GvHD). To generate preclinical data we developed mouse models to study anti-leukemic- and anti-tumor-potential of CIK cells in vivo. Immunodeficient mice (NOD/SCID/IL-2Rγc−, NSG) were injected intravenously with human leukemic cell lines THP-1, SH-2 and with human rhabdomyosarcoma (RMS) cell lines RH41 and RH30 at minimal doses required for leukemia or tumor engraftment. Mice transplanted with THP-1 or RH41 cells were randomly assigned for analysis of CIK cell treatment. Organs of mice were analyzed by flow cytometry as well as quantitative polymerase chain reaction for engraftment of malignant cells and CIK cells. Potential of CIK cells to induce GvHD was determined by histological analysis. Tissues of the highest degree of THP-1 cell expansion included bone marrow followed by liver, lung, spleen, peripheral blood (PB), and brain. RH30 and RH41 engraftment mainly took place in liver and lung, but was also detectable in spleen and PB. In spite of delayed CIK cell expansion compared with malignant cells, CIK cells injected at equal amounts were sufficient for significant reduction of RH41 cells, whereas against fast-expanding THP-1 cells 250 times more CIK than THP-1 cells were needed to achieve comparable results. Our preclinical in vivo mouse models showed a reliable 100% engraftment of malignant cells which is essential for analysis of anti-cancer therapy. Furthermore our data demonstrated that IL-15-activated CIK cells have potent cytotoxic capacity against AML and RMS cells without causing GvHD.
- 30 September 2011
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 24 (3) , 443-452
Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children
- 30 September 2011
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 24 (3) , 443-452
Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children
- 1 October 2005
- Published by Springer Nature in Der Onkologe
- Vol. 11 (10) , 1047-1053
Weichteilsarkome im Kindesalter
- 1 October 2005
- Published by Springer Nature in Der Onkologe
- Vol. 11 (10) , 1047-1053
Weichteilsarkome im Kindesalter
- 1 January 2002
- Published by Springer Nature in Pediatric Drugs
- Vol. 4 (1) , 21-28
Soft Tissue Sarcoma in Children
- 1 January 2002
- Published by Springer Nature in Pediatric Drugs
- Vol. 4 (1) , 21-28
Soft Tissue Sarcoma in Children